MAYAKU PHARMACEUTICAL DEVELOPMENT
0755.350.975 · rovalta.com · 05/11/2026
ACTIVE
MAYAKU PHARMACEUTICAL DEVELOPMENT
Financial year 2025 · Closed on 31/12/2025
Net result1,6 k €-67,5 %over 1 year
Gross margin104,8 k €+115,0 %over 1 year
Equity1,3 k €+592,4 %over 1 year
Overview
Identity
Source · BCE/KBOMAYAKU PHARMACEUTICAL DEVELOPMENT is a Private limited company incorporated in 2020. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Gent.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0755.350.975
- Incorporation
- 29/09/2020
- Legal form
- Private limited company
- Registered office
- Technologiepark-Zwijnaarde 82
9052 Gent · FlandreSee on map - Contributed capital
- 2 000,00 €
- Latest accounts
- 31/12/2025
Activities (NACE)
Signals
ProfitableGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Financials
Source · NBB, 5 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 104,8 k € | +115% | 48,7 k € | +392% | -16,7 k € | -40.4% | -11,9 k € | -128% | 43,1 k € |
| EBITDA | 19,1 k € | +7.1% | 17,8 k € | +202% | -17,6 k € | -44.7% | -12,1 k € | -128% | 42,6 k € |
| Operating result | 4,2 k € | -32.8% | 6,3 k € | +126% | -24 k € | -73.3% | -13,8 k € | -135% | 39,3 k € |
| Net result | 1,6 k € | -67.5% | 4,8 k € | +119% | -25,5 k € | -72.9% | -14,7 k € | -144% | 33,2 k € |
| Balance sheet | |||||||||
| Equity | 1,3 k € | +592% | -262,1 € | +94.8% | -5 k € | -125% | 20,4 k € | -41.9% | 35,2 k € |
| Total assets | 170,5 k € | +72.0% | 99,1 k € | +6.5% | 93,1 k € | +57.2% | 59,2 k € | -39.9% | 98,4 k € |
| Cash | 76,4 k € | +227% | 23,4 k € | -51.5% | 48,2 k € | +212% | 15,5 k € | -79.8% | 76,6 k € |
| Debts | 169,2 k € | +70.2% | 99,4 k € | +1.3% | 98,1 k € | +153% | 38,7 k € | -38.7% | 63,2 k € |
Valuation
Indicative valuation
As an indication, this company is worth
between 0 € and 100 k€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Michiel Van Speybroeck | DirectorManager2023 accountsended |
Other companies at this address
Technologiepark-Zwijnaarde 82 9052 Gent| Company | CBE no. |
|---|---|
Amalus Therapeutics● Bankrupt | 0803.929.268 |
APCOR R&M● Active | 0600.952.909 |
Ardoyen● Active | 0875.102.821 |
AVROXA● Active | 0687.774.936 |
Benebiose● Active | 0784.521.548 |
BioNeering● Active | 0807.194.309 |
CONTREL EUROPE● Active | 0426.204.637 |
CRODEON TECHNOLOGIES● Active | 0642.754.761 |
Cryptobiotix● Active | 0762.565.104 |
Gulliver Biomed● Active | 0692.527.837 |
ImplicitMeasures.com● Bankrupt | 0657.989.701 |
Inbiose● Active | 0534.887.593 |
| 0440.054.752 | |
INNOVATIVE PHARMACEUTICS● Active | 0883.574.582 |
Inspect● Active | 0645.950.417 |
INVIBES ADVERTISING● Active | 0836.533.938 |
KYTOS● Active | 0768.755.286 |
Lares Solutions● Active | 1015.346.906 |
| 0742.910.132 | |
| 0667.765.816 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 29/09/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 16 months |
| Filing date | 04/07/2026 | 27/06/2025 | 18/06/2024 | 29/06/2023 | 19/07/2022 |
| General meeting | 22/06/2026 | 22/06/2025 | 01/06/2024 | 01/06/2023 | 20/06/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 5 filingsValuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 0 € and 100 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Michiel Van Speybroeck | DirectorManager2023 accountsended |
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsYear
Identity
Incorporation
Name
Registered office
Annual accounts
Filings5 filings
Mandates
Michiel Van Speybroeck
2020202120222023202420252026
MAYAKU PHARMACEUTICAL DEVELOPMENT
Technologiepark-Zwijnaarde 82, 9052 Zwijnaarde
Director
CurrentPlanned, not yet servedEndedAccounts filedToday
Registered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Technologiepark-Zwijnaarde 82, 9052 ZwijnaardeCurrent | accounts 2022 → 2025 | Accounts 2025 · 2026-00264059 |
| Hamerstraat 41, 9000 Gent | accounts 2021 | Accounts 2021 · 2022-20226534 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| MAYAKU PHARMACEUTICAL DEVELOPMENTCurrent | accounts 2021 → 2025 | Accounts 2025 · 2026-00264059 |
Events
- 2025Annual accounts 20251,6 k €↓
- 2024Annual accounts 20244,8 k €↑
- 2023Annual accounts 2023-25,5 k €↓
- 2022Annual accounts 2022-14,7 k €↓
- 2021Annual accounts 202133,2 k €
- 29/09/2020IncorporationPrivate limited company